170 related articles for article (PubMed ID: 37957632)
1. Synergetic regulation of cancer cells and exhausted T cells to fight cold tumors with a fluorinated EGCG-based nanocomplex.
Zhang J; Wang M; He D; Zhang L; Liu T; Wang K
J Nanobiotechnology; 2023 Nov; 21(1):420. PubMed ID: 37957632
[TBL] [Abstract][Full Text] [Related]
2. Microfluidics-enabled fluorinated assembly of EGCG-ligands-siTOX nanoparticles for synergetic tumor cells and exhausted t cells regulation in cancer immunotherapy.
Han X; Zhang G; Wu X; Xu S; Liu J; Wang K; Liu T; Wu P
J Nanobiotechnology; 2024 Mar; 22(1):90. PubMed ID: 38439048
[TBL] [Abstract][Full Text] [Related]
3. Engineered EGCG-Containing Biomimetic Nanoassemblies as Effective Delivery Platform for Enhanced Cancer Therapy.
Wu P; Zhang H; Yin Y; Sun M; Mao S; Chen H; Deng Y; Chen S; Li S; Sun B
Adv Sci (Weinh); 2022 May; 9(15):e2105894. PubMed ID: 35486032
[TBL] [Abstract][Full Text] [Related]
4. Manipulating Offense and Defense Signaling to Fight Cold Tumors with Carrier-Free Nanoassembly of Fluorinated Prodrug and siRNA.
Wu P; Zhang H; Sun M; Mao S; He Q; Shi Y; Deng Y; Dong Z; Xu Q; Zhao C; Zhang W; Sun B
Adv Mater; 2022 Sep; 34(38):e2203019. PubMed ID: 35918816
[TBL] [Abstract][Full Text] [Related]
5. Ovarian cancer immunotherapy using PD-L1 siRNA targeted delivery from folic acid-functionalized polyethylenimine: strategies to enhance T cell killing.
Teo PY; Yang C; Whilding LM; Parente-Pereira AC; Maher J; George AJ; Hedrick JL; Yang YY; Ghaem-Maghami S
Adv Healthc Mater; 2015 Jun; 4(8):1180-9. PubMed ID: 25866054
[TBL] [Abstract][Full Text] [Related]
6. Co-delivery of EGCG and melittin with self-assembled fluoro-nanoparticles for enhanced cancer therapy.
Sun M; Wu Y; Zhou Z; Liu S; Mao S; Li G
Aging (Albany NY); 2023 Jun; 15(11):4875-4888. PubMed ID: 37277118
[TBL] [Abstract][Full Text] [Related]
7. Targeting pulmonary tumor microenvironment with CXCR4-inhibiting nanocomplex to enhance anti-PD-L1 immunotherapy.
Li Z; Wang Y; Shen Y; Qian C; Oupicky D; Sun M
Sci Adv; 2020 May; 6(20):eaaz9240. PubMed ID: 32440550
[TBL] [Abstract][Full Text] [Related]
8. A size-shrinkable matrix metallopeptidase-2-sensitive delivery nanosystem improves the penetration of human programmed death-ligand 1 siRNA into lung-tumor spheroids.
Wen J; Qiu N; Zhu Z; Bai P; Hu M; Qi W; Liu Y; Wei A; Chen L
Drug Deliv; 2021 Dec; 28(1):1055-1066. PubMed ID: 34078185
[TBL] [Abstract][Full Text] [Related]
9. Programmed Cell Death-1: Programmed Cell Death-Ligand 1 Interaction Protects Human Cardiomyocytes Against T-Cell Mediated Inflammation and Apoptosis Response In Vitro.
Tay WT; Fang YH; Beh ST; Liu YW; Hsu LW; Yen CJ; Liu PY
Int J Mol Sci; 2020 Mar; 21(7):. PubMed ID: 32244307
[TBL] [Abstract][Full Text] [Related]
10. A review of PD-1/PD-L1 siRNA delivery systems in immune T cells and cancer cells.
Barati M; Mirzavi F; Atabaki M; Bibak B; Mohammadi M; Jaafari MR
Int Immunopharmacol; 2022 Oct; 111():109022. PubMed ID: 35987146
[TBL] [Abstract][Full Text] [Related]
11. Hemagglutinating virus of Japan-envelope containing programmed cell death-ligand 1 siRNA inhibits immunosuppressive activities and elicits antitumor immune responses in glioma.
Sugii N; Matsuda M; Okumura G; Shibuya A; Ishikawa E; Kaneda Y; Matsumura A
Cancer Sci; 2021 Jan; 112(1):81-90. PubMed ID: 33155337
[TBL] [Abstract][Full Text] [Related]
12. Immune checkpoint expression on peripheral cytotoxic lymphocytes in cervical cancer patients: moving beyond the PD-1/PD-L1 axis.
Solorzano-Ibarra F; Alejandre-Gonzalez AG; Ortiz-Lazareno PC; Bastidas-Ramirez BE; Zepeda-Moreno A; Tellez-Bañuelos MC; Banu N; Carrillo-Garibaldi OJ; Chavira-Alvarado A; Bueno-Topete MR; Del Toro-Arreola S; Haramati J
Clin Exp Immunol; 2021 Apr; 204(1):78-95. PubMed ID: 33306195
[TBL] [Abstract][Full Text] [Related]
13. Blockage of immune checkpoint molecules increases T-cell priming potential of dendritic cell vaccine.
Hassannia H; Ghasemi Chaleshtari M; Atyabi F; Nosouhian M; Masjedi A; Hojjat-Farsangi M; Namdar A; Azizi G; Mohammadi H; Ghalamfarsa G; Sabz G; Hasanzadeh S; Yousefi M; Jadidi-Niaragh F
Immunology; 2020 Jan; 159(1):75-87. PubMed ID: 31587253
[TBL] [Abstract][Full Text] [Related]
14. Single-cell transcriptome analysis reveals TOX as a promoting factor for T cell exhaustion and a predictor for anti-PD-1 responses in human cancer.
Kim K; Park S; Park SY; Kim G; Park SM; Cho JW; Kim DH; Park YM; Koh YW; Kim HR; Ha SJ; Lee I
Genome Med; 2020 Feb; 12(1):22. PubMed ID: 32111241
[TBL] [Abstract][Full Text] [Related]
15. Immune checkpoint silencing using RNAi-incorporated nanoparticles enhances antitumor immunity and therapeutic efficacy compared with antibody-based approaches.
Won JE; Byeon Y; Wi TI; Lee CM; Lee JH; Kang TH; Lee JW; Lee Y; Park YM; Han HD
J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35228265
[TBL] [Abstract][Full Text] [Related]
16. Stearyl polyethylenimine complexed with plasmids as the core of human serum albumin nanoparticles noncovalently bound to CRISPR/Cas9 plasmids or siRNA for disrupting or silencing PD-L1 expression for immunotherapy.
Cheng WJ; Chen LC; Ho HO; Lin HL; Sheu MT
Int J Nanomedicine; 2018; 13():7079-7094. PubMed ID: 30464460
[TBL] [Abstract][Full Text] [Related]
17. Tumor immunosuppression relief via acidity modulation combined PD-L1 siRNA for enhanced immunotherapy.
Tang Y; Chang Q; Chen G; Zhao X; Huang G; Wang T; Jia C; Lu L; Jin T; Yang S; Cao L; Zhang X
Biomater Adv; 2023 Jul; 150():213425. PubMed ID: 37084635
[TBL] [Abstract][Full Text] [Related]
18. Secretion of human soluble programmed cell death protein 1 by chimeric antigen receptor-modified T cells enhances anti-tumor efficacy.
Zhang A; Sun Y; Wang S; Du J; Gao X; Yuan Y; Zhao L; Yang Y; Xu L; Lei Y; Duan L; Xu C; Ma L; Wang J; Hu G; Chen H; Wang Q; Hu L; Zhang B
Cytotherapy; 2020 Dec; 22(12):734-743. PubMed ID: 32684339
[TBL] [Abstract][Full Text] [Related]
19. WDR5-H3K4me3 epigenetic axis regulates OPN expression to compensate PD-L1 function to promote pancreatic cancer immune escape.
Lu C; Liu Z; Klement JD; Yang D; Merting AD; Poschel D; Albers T; Waller JL; Shi H; Liu K
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34326167
[TBL] [Abstract][Full Text] [Related]
20. PD-1 silencing improves anti-tumor activities of human mesothelin-targeted CAR T cells.
Liu G; Zhang Q; Li D; Zhang L; Gu Z; Liu J; Liu G; Yang M; Gu J; Cui X; Pan Y; Tian X
Hum Immunol; 2021 Feb; 82(2):130-138. PubMed ID: 33341289
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
